In the tumor microenvironment, CD11b 
Introduction
The tumor microenvironment provides primary tumor cells to mix with multiple types of stroma such as endothelium, fibroblasts, and immune cells (1) . Such heterogeneity of cell populations presents a major impediment for developing a cure for cancer. Increasing evidence supports that stromal cells in the tumor microenvironment not only occupy a significant fraction of the tumor bulk, but also play critical roles in proliferation, invasion, and/or metastasis of tumor cells (2) . In this regard, bone is an essential partner for tumor progression, because bone marrow serves as the supplying organ for numerous critical cells in the tumor microenvironment (3, 4) . However, it is unclear how tumor cells co-opt the bone and/or bone marrow to facilitate a favorable tumor microenvironment.
Among the bone marrow-derived cells, CD11b
þ Gr1 þ cells
[commonly referred to as myeloid-derived suppressor cells (MDSC)] correlate with tumor progression (5) . MDSCs were originally investigated for their roles in evasion of host immune surveillance, especially via suppression of T-cell-dependent antitumoral immunity by production of arginase, reactive oxygen species, and inducible nitric oxide synthase (6) . Subsequent studies demonstrated that MDSCs are increased in tumor-bearing mice and cancer patients, and infiltrate primary tumor tissue to promote angiogenesis by secreting matrix metalloproteinases (MMP), and also by direct incorporation into tumor endothelium (7, 8) . More recently, MDSCs have been shown to play key roles in recovery after radiation therapy (9, 10) and antiangiogenic therapy (11) . In parallel, multiple mechanisms have been proposed to explain the increased recruitment of MDSCs in tumor tissue. Yang and colleagues demonstrated that CXC chemokine ligand (CXCL)-5/CXC receptor (CXCR)-2 and stromal-derived factor-1/CXCR-4 axes recruit circulating MDSCs to tumor tissue (12) . More recently, expression of a single integrin (a4b1) promotes MDSC invasion into tumors via activation of phosphatidylinositol 3-kinase (PI3K; ref. 13 ). However, despite such clear evidence supporting the tumorigenic functions of MDSCs and also the potential mechanisms of recruitment to the tumor tissue, MDSCs are poorly understood about their regulation in the supplying organ (i.e., bone marrow) of the tumor host, and also their potential crosstalk with distant primary tumor cells.
This study was designed to elucidate how CD11b
þ Gr1 þ cells are regulated in the bone marrow of prostate tumor hosts, contributing to tumor growth and angiogenesis. Prostate cancer provides a unique perspective on this process because of its devastating mortality and morbidity associated with its preferential metastasis to the skeleton (14) . Accordingly, prostate cancer cells secrete numerous important bone-modulating cytokines, leading to osteoblastic/osteolytic reactions that facilitate growth factor and cytokine release from bone cells and matrix (15) . In particular, parathyroid hormone-related protein (PTHrP) is expressed by prostate cancer cells, and stimulates osteoblasts in an endocrine manner to secrete factors such as receptor activator of NF-kB ligand (RANKL), interleukin (IL)-6, C-C chemokine ligand (CCL)-2, and VEGF-A within the bone microenvironment (16) (17) (18) 
Materials and Methods

Cells
Two luciferase-labeled PC-3 clones expressing high and low levels of PTHrP were selected from previously established stable-shRNA clones targeting PTHLH (19), designating PTHrP Hi and PTHrP Lo , respectively. Ace-1 canine prostate carcinoma cells, expressing undetectable basal levels of PTHrP, were stably transfected with a pcDNA3.1 vector expressing fulllength mouse/rat PTHrP (17) . An empty-vector transfectant was used as a control. Expression of PTHrP was confirmed from the culture supernatant using an immunoradiometric assay kit (Diagnostic Laboratories). PC-3 clones were regularly authenticated and matched short tandem repeat DNA profiles of the original PC-3 cell line (last tested on August 28, 2012).
Mice and in vivo tumors
All mouse experiments were approved by the Institutional Animal Care and Use Committees of the University of Michigan and Vanderbilt University. For in vivo tumors, 1 Â 10 6 prostate tumor cells were suspended in 100 mL Hank's balanced salt solution and 1:1 mixed with growth factor-reduced Matrigel (BD Biosciences), followed by subcutaneous injection into male athymic mice (Harlan Laboratories) as previously described (20, 21) . Mice were regularly monitored for morbidity or tumor growth, and tumor size was calculated using an
, where a is the long diameter and b is the short diameter measured with a caliper (22) . Antihuman PTHrP 1 to 33 monoclonal antibodies (hybridoma 158) were produced and generously gifted by Dr. R. Kremer 
Immunohistochemistry
Tumors were surgically removed and bisected, a portion fixed in formalin and a portion snap-frozen. Murine endothelial cell-specific CD31/PECAM immunostaining (clone MEC13.3; BD Biosciences) was performed according to a previously described method (24) . Rat anti-mouse CD11b (clone M1/70; BD Biosciences) and anti-mouse Ly-6G (clone RB6-8C5; eBioscience) were fluorescently labeled and used to detect CD11b þ Gr1 þ cells in the tumor tissue. Three to five randomly selected microscopic images per sample were obtained, and positively stained cells were counted using ImageJ software.
Quantitative PCR mRNA samples were prepared from the bone marrow or tumor tissues using TRIzol reagent (Invitrogen), followed by reverse transcription-quantitative PCR (25) . All quantitative PCR probes and reagents were from Applied Biosystems.
Statistical analyses
All in vivo data sets were tested for normality by ShapiroWilk test. Statistical analyses were performed by GraphPad Prism software. Student t test or Mann-Whitney U test were used to compare 2 groups and all statistical tests were 2-sided.
Results
Reduction of PTHrP in PC-3 prostate tumors decreased CD11b þ
Gr1
þ bone marrow cell recruitment and angiogenesis As a first approach to investigate the role of PTHrP in the potential crosstalk between tumor and the bone marrow, the PTHLH gene (encoding PTHrP) was targeted via lentiviral shRNA vectors in PC-3, human prostate cancer cells (19 ; measured in the culture supernatant by immunoradiometric assays) were selected and designated PTHrP Hi and PTHrP Lo , respectively. PTHrP is well known to regulate tumor growth via autocrine, intracrine, and paracrine manners (17-19, 26, 27) , hence alterations in the host response (e.g., recruitment of hostderived cells) could simply be secondary to the differences in the tumor size, not in PTHrP expression levels. Therefore, PTHrP Lo tumors were grown for a longer period until they reached a similar mean tumor volume as PTHrP Hi tumors to circumvent the direct tumor-size effects in the subsequent analyses ( Fig. 1A and B) . Flow cytometric analyses of the tumor tissues revealed that PTHrP Lo tumors had significantly reduced percentages of CD11b
þ cells in the tumor tissue compared with PTHrP Hi tumors (Fig. 1C) . Immunohistological analyses showed PTHrP levels correlated with mean vessel density and vessel area of PC-3 tumors (Fig. 1D-F) . A well-characterized mechanism of MDSC-dependent tumor angiogenesis is through the expression of MMP-9 (7, 28) . Accordingly, tumor tissues were analyzed for expression of host-derived MMP-9 expression as well as tumor-derived VEGF-A ( Fig. 1G and H) using species-specific PCR probes. PTHrP Lo tumors had significantly reduced host-derived (i.e., murine) Mmp9 expression, whereas no significant reduction in the tumor-derived (i.e., human) VEGFA was observed. Collectively, reduction of PTHrP in PC-3 prostate tumors decreased CD11b þ Gr1 þ cell recruitment and tumor angiogenesis, in association with reduced expression of host MMP-9 but not of tumor VEGF-A. Fig. 2A and Supplementary  Fig. S1 ). Both PTHrP OE and recombinant PTHrP-treated groups had significantly increased CD11b þ Gr1 þ cells in the tumor tissue compared with pcDNA control tumors (Fig. 2B) . Although mice burdened with PTHrP OE tumors had Mean tumor volume between the 2 groups was not significantly different (P ¼ 0.68, Student t test). Scale bar, 1 cm. C, percentages of CD11b þ Gr1 þ doublepositive cells in the tumor tissues were analyzed by flow cytometry. D, tumor tissues were sectioned for H&E and murine CD31/PECAM immunohistochemical staining. Original magnification, Â20. Scale bars, 50 mm. E and F, microscopic images were analyzed for tumor mean vessel density (MVD) or CD31 þ vascular area with normalization to total nuclear area. G and H, host-derived (i.e., murine) Mmp9 and tumor-derived (i.e., human) VEGFA mRNA levels were measured by quantitative RT-PCR using species-specific probes (n ¼ 9-10 per group). All P values are from Student t test. NS, not significant. Data in all graphs are mean AE SEM.
Ectopic PTHrP increased the recruitment of CD11b
significantly increased percentages of CD11b þ Gr1 þ cells in the bone marrow (Fig. 2C) , recombinant PTHrP treatment failed to show such an increase in the bone marrow. This may be explained by either the different modes of PTHrP administration (i.e., intermittent injection vs. continuous expression) or the reduced duration (7 days) of PTHrP treatment compared with tumor burden (21 days). Immunohistochemical analyses of tumor tissue showed that both PTHrP OE and recombinant PTHrP tumors had significantly increased evidence of angiogenesis ( Fig. 2D and Supplementary Fig. S1B ). In addition, host-derived Mmp9 expression was significantly increased in PTHrP OE tumor tissue (Fig. 2E) (Fig. 3A) .
Increasing numbers of CD11b (Fig. 4B) , potentially because increased MMP-9 and angiogenesis as determined by immunohistochemistry (Fig. 4C and D and Supplementary Fig. S2 ).
PTHrP increased expression of phospho-[Y 418 ] Src family kinases in CD11b
The molecular mechanism for the observed PTHrP-dependent CD11b þ Gr1 þ cell potentiation was subsequently investigated. Recently, Liang and colleagues demonstrated that dasatinib, an SFK inhibitor, suppressed prostate tumor growth as well as the numbers of CD11b þ myeloid cells in tumor tissues (32) . Accordingly, the effects of PTHrP administration 
CD11b
þ Gr1 þ cell activation were examined in combination with PTHrP-dependent osteoblastic cytokines and an SFK selective inhibitor, PP2 (5, 13, 28) . Only VEGF-A and IL-6 increased Mmp9 gene expression, whereas Cxcr2, Cxcr4, or Itgb1 expression remained unaffected in CD11b
and this increase was reversed by PP2 treatment (Fig. 6A-D) . 
were sorted from the femoral bone marrow of male athymic mice via flow cytometry, followed by treatment with saline (control), VEGF-A, IL-6, PTHrP, or CCL-2 (100 ng/mL for 0.5 Â 10 6 cells) in combination with PP2 (an SFK inhibitor; 100 nmol/L) or dimethyl sulfoxide (DMSO) control for 1 hour at 37 C (n ¼ 3 per group). mRNA levels of Mmp9, Cxcr4, Cxcr2, and Itgb1 were determined via quantitative RT-PCR. Data are mean AE SEM. Ã , P < 0.01 compared with the DMSO control group. No other combination had statistical significance (P > 0.05, Student t test). E-G, conditioned media were collected from primary calvarial osteoblasts stimulated with saline (control) or PTHrP . Femoral bone marrow CD11b
þ cells were treated with the control or PTHrP-conditioned media in combination with neutralizing antibodies against VEGF-A and/or IL-6, followed by quantitative PCR (E) for Mmp9 gene expression (n ¼ 3 per group) or zymography (F). Data are mean AE SEM. Ã , P < 0.05; NS, not significant by Student t test. G, CD11b þ Gr1 þ cells were treated with control or PTHrP-conditioned media in combination with PP2 or DMSO control, followed by zymography. Furthermore, to confirm the requirement of osteoblasts in PTHrP-dependent potentiation of CD11b þ Gr1 þ cells, primary osteoblasts were established from murine calvaria and treated with PTHrP (1-34) or saline for 24 hours and conditioned media harvested (39) . CD11b þ Gr1 þ cells were isolated from femoral bone marrow and stimulated with osteoblast-derived control-or PTHrP-conditioned media in combination with neutralizing antibodies against VEGF-A and/or IL-6. Consistent with the previous data, PTHrP-conditioned media from osteoblast cultures increased Mmp9 gene expression (Fig. 6E ) and functional MMP-9 ( Fig. 6F ) in the MDSCs, and these effects were blocked by anti-VEGF-A and/or anti-IL-6 neutralizing antibodies. Furthermore, the effect of PTHrP-conditioned media on MMP-9 expression was suppressed by PP2 (Fig. 6G) .
Anti-PTHrP monoclonal antibody treatment decreased MDSC recruitment in PC-3 tumors Finally, to more rigorously determine the causal relationship between PTHrP and MDSC recruitment, mice bearing
PTHrP
Hi PC-3 tumors were treated with nonspecific control IgG or anti-human PTHrP monoclonal antibodies. AntiPTHrP antibodies significantly suppressed tumor growth, but not to the level of PTHrP Lo tumors (Fig. 7A and B) . As anti-PTHrP monoclonal antibodies potentially suppress tumor growth via inhibition of autocrine PTHrP effects on tumor cells (Supplementary Fig. S4 ), tumor tissues were analyzed for MDSC recruitment by immunofluorescence colocalization of CD11b þ
Gr1
þ cells (Fig. 7C and D) . Numbers of CD11b þ Gr1 þ cells were decreased in anti-PTHrP antibody-treated or PTHrP Lo tumor tissues, suggesting that reduced PTHrP is causal to decreased MDSCs found in tumor tissues. Serum calcium levels were correlated with PTHrP levels, indicating the functional activity of PTHrP (Fig. 7E) . Quantitative RT-PCR analysis in tumor tissues revealed that shRNA-mediated PTHrP knockdown was stable in PC-3 tumor cells during in vivo tumor growth, and the correlation between PTHrP and Mmp9 gene expression ( Fig. 7F and G) . 
Discussion
This study provides new evidence that distant tumors stimulate the bone marrow to increase critical component cells in the tumor microenvironment. In brief, prostate cancer-derived PTHrP circulates to potentiate CD11b þ Gr1 þ cells within the bone marrow via upregulation of IL-6 and VEGF-A in osteoblasts, contributing to tumor growth and angiogenesis (Fig. 8) . As a proposed mechanism of CD11b þ Gr1 þ cell potentiation, these data demonstrate that PTHrP increased activating phosphorylation of SFKs that subsequently increased Mmp9 gene expression in CD11b
growth is, at least in part, mediated by MMP-9 expression and angiogenesis. Increasing evidence now clearly supports the critical functions of CD11b þ Gr1 þ MDSCs in the tumor microenvironment (40) . However, the majority of previous studies have been focused either on the roles of MDSCs within the tumor microenvironment (i.e., immune suppression and angiogenesis) or the mechanism of MDSC recruitment to the tumor (41, 42) . Given that bone is an essential partner for tumor progression by supplying numerous bone marrow-derived stromal cells, primary tumor cells are speculated to have active mechanisms to interact with the bone/bone marrow (43, 44) . The data in this study demonstrate that PTHrP serves as a messenger between the primary tumor and the bone marrow, conferring MDSCs with increased angiogenic potential. PTHrP is a potent bone-modulating cytokine expressed by multiple types of tumor cells such as prostate, breast, lung, and colorectal cancers (45) (46) (47) (48) . In addition, PTHrP is a key regulator of the "vicious cycle" hypothesis of metastatic tumor-bone interactions (49) . However, given that MDSCs are currently considered universally essential components of the tumor microenvironment, not all tumor types express PTHrP, suggesting that PTHrP is not the only factor mediating the interactions between tumor and bone. The molecular mechanisms of MDSC activation, expansion, and/or mobilization, and ultimately therapeutic approaches targeting the key signaling mechanisms, warrant extensive further investigation. Interestingly, the preliminary studies shown in Supplementary Fig. S5 suggest that PTHrP induces a series of alterations in the bone marrow to mobilize and/or expand MDSCs. Still, questions remain about whether and how PTHrP stimulates differentiation of MDSCs from bone marrow precursors. Nevertheless, this work provides a biological rationale for the clinical application of SFK inhibitors in targeting 2 compartments (i.e., tumor and the microenvironment) simultaneously, of which the mechanism requires further studies. The data in this study demonstrate that activation of SFKs is one of the key signal transduction mechanisms of MDSCs' angiogenic potential, in addition to two other factors, STAT3 and PI3K, that have previously been shown to be implicated in MDSC functions (13, 31) . Indeed, SFKs mediate crucial regulatory functions in both tumor cells and stromal cells (e.g., endothelial cells and osteoclasts), suggesting that SFKs are promising therapeutic targets for the suppression of tumor as well as stromal compartments (24, 50) .
In conclusion, this study provides evidence that prostate cancers positively regulate the bone marrow microenvironment via PTHrP, IL-6, VEGF-A, and SFKs, thereby increasing the angiogenic potential of CD11b þ Gr1 þ MDSCs, leading to increased tumor growth.
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